{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:19:25Z","timestamp":1792513165846,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has achieved notable efficacy in relapsed\/refractory multiple myeloma (RRMM), yet most patients eventually relapse, highlighting the need to elucidate mechanisms of resistance. In this study, we investigated the role of TIGIT in resistance to BCMA-CAR-T therapy. Tumor-infiltrating T cells from RRMM patients receiving BCMA-CAR-T therapy were analyzed by single-cell RNA sequencing, and immune checkpoint expression was further assessed by flow cytometry. Functional assays, including luciferase-based cytotoxicity, CD107a degranulation, CFSE proliferation, and CD45RO\/CD62L phenotyping, were performed to investigate the effects of TIGIT inhibition through knockout or anti-TIGIT monoclonal antibodies (mAbs). In a humanized immune cell-reconstituted mouse model, TIGIT blockade was further evaluated for its effects on tumor growth and T cell exhaustion. T cells from patients with early relapse exhibited higher TIGIT expression than those from patients with durable responses, and elevated TIGIT levels were correlated with increased tumor burden and poor prognosis. While TIGIT blockade exerted limited effects on CAR-T function in vitro, it markedly enhanced CAR-T proliferation, mitigated T cell exhaustion, and improved antitumor efficacy in vivo, particularly when mediated by anti-TIGIT mAbs. Transcriptomic profiling further revealed that TIGIT modulates CAR-T activity by regulating cytokines and chemokines pathways and T cell activation, findings that were preliminarily validated by functional assays. Collectively, these findings identify TIGIT as a critical regulator of resistance to BCMA-CAR-T therapy and highlight TIGIT blockade as a promising strategy to enhance CAR-T efficacy and overcome relapse in multiple myeloma.<\/jats:p>","DOI":"10.1038\/s41419-025-08203-w","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:27:48Z","timestamp":1766154468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-4955","authenticated-orcid":false,"given":"Yuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-6701","authenticated-orcid":false,"given":"Jianfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-1463","authenticated-orcid":false,"given":"Xuxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-4987","authenticated-orcid":false,"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1194","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"8203_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15:86.","journal-title":"J Hematol Oncol"},{"key":"8203_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/07853890.2021.1970218","volume":"53","author":"L Zhang","year":"2021","unstructured":"Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, et al. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med. 2021;53:1547\u201359.","journal-title":"Ann Med"},{"key":"8203_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.11.004","volume":"65","author":"S Lesch","year":"2020","unstructured":"Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2020;65:80\u201390.","journal-title":"Semin Cancer Biol"},{"key":"8203_CR4","doi-asserted-by":"crossref","unstructured":"Holthof LC, Mutis T. Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance. Cancers. 2020;12:988.","DOI":"10.3390\/cancers12040988"},{"key":"8203_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"8203_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101447","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Li Z, Huang B, Xu L, Lai J, et al. Single-cell RNA-seq of T cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity. Adv Sci. 2021;8:e2101447.","journal-title":"Adv Sci"},{"key":"8203_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"8203_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1278749","volume":"14","author":"Y Xia","year":"2023","unstructured":"Xia Y, Zhao Q, Shen X, Jin Y, Wang J, Zhu J, et al. Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma. Front Immunol. 2023;14:1278749.","journal-title":"Front Immunol"},{"key":"8203_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19:37\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"8203_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, Van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"8203_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858021","volume":"13","author":"W Sang","year":"2022","unstructured":"Sang W, Wang X, Geng H, Li T, Li D, Zhang B, et al. Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed\/refractory CD30+ lymphoma. Front Immunol. 2022;13. 858021.","journal-title":"Front Immunol"},{"key":"8203_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res. 2021;27:473\u201384.","journal-title":"Clin Cancer Res"},{"key":"8203_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101085","volume":"14","author":"X Liu","year":"2021","unstructured":"Liu X, Zhang Y, Li K, Liu Y, Xu J, Ma J, et al. A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma. Transl Oncol. 2021;14:101085.","journal-title":"Transl Oncol"},{"key":"8203_CR14","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","volume":"6","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6:e459\u2013e469.","journal-title":"Lancet Haematol"},{"key":"8203_CR15","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.17448","volume":"194","author":"P Moreau","year":"2021","unstructured":"Moreau P, Ghori R, Farooqui M, Marinello P, San Miguel J. Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: cohort 2 of the phase I KEYNOTE-023 study. Br J Haematol. 2021;194:e48\u2013e51.","journal-title":"Br J Haematol"},{"key":"8203_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2529632","volume":"14","author":"A Oliver-Caldes","year":"2025","unstructured":"Oliver-Caldes A, Mane Pujol J, Battram AM, Perez-Amill L, Bachiller M, Calderon H, et al. TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model. Oncoimmunology. 2025;14:2529632.","journal-title":"Oncoimmunology"},{"key":"8203_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"8203_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang C, Qiao M, Cheng C, Tang N, Lu S, et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell. 2022;40:1407\u201322 e1407.","journal-title":"Cancer Cell"},{"key":"8203_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. nCounter(\u00ae) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA). J Immunother Cancer. 2015;3:42.","journal-title":"J Immunother Cancer"},{"key":"8203_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01655-0","volume":"21","author":"VC Jiang","year":"2022","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022;21:185.","journal-title":"Mol Cancer"},{"key":"8203_CR21","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson Z, Hong C, Schauner R, Dropulic B, Caimi PF, De Lima M, et al. Sequential single-cell transcriptional and protein marker profiling reveals tigit as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discov. 2022;12:1886\u2013903.","journal-title":"Cancer Discov"},{"key":"8203_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1866287","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, Peticone C, Kotsopoulou E, Gottgens B, Calero-Nieto FJ. Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures. Oncoimmunology. 2021;10:1866287.","journal-title":"Oncoimmunology"},{"key":"8203_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48\u201357.","journal-title":"Nat Immunol"},{"key":"8203_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12:7.","journal-title":"Biomark Res"},{"key":"8203_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57:206\u201322.","journal-title":"Immunity"},{"key":"8203_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s40425-019-0785-8","volume":"7","author":"HR Kim","year":"2019","unstructured":"Kim HR, Park HJ, Son J, Lee JG, Chung KY, Cho NH, et al. Tumor microenvironment dictates regulatory T cell phenotype: upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019;7:339.","journal-title":"J Immunother Cancer"},{"key":"8203_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","volume":"26","author":"RS Finn","year":"2025","unstructured":"Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2 study. Lancet Oncol. 2025;26:214\u201326.","journal-title":"Lancet Oncol"},{"key":"8203_CR28","doi-asserted-by":"publisher","first-page":"S4717","DOI":"10.1182\/blood-2021-148052","volume":"138","author":"M Frenkel","year":"2021","unstructured":"Frenkel M, Alteber Z, Xu N, Li M, Chen H, Cojocaru G, et al. Dominant expression of pvrig and tigit inhibitory pathways in bone marrow of multiple myeloma patients. Blood. 2021;138:S4717\u2013S4719.","journal-title":"Blood"},{"key":"8203_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12:99.","journal-title":"Exp Hematol Oncol"},{"key":"8203_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","volume":"132","author":"C Guillerey","year":"2018","unstructured":"Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K, et al. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood. 2018;132:1689\u201394.","journal-title":"Blood"},{"key":"8203_CR31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","volume":"132","author":"SA Minnie","year":"2018","unstructured":"Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132:1675\u201388.","journal-title":"Blood"},{"key":"8203_CR32","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","volume":"5","author":"S Richard","year":"2024","unstructured":"Richard S, Lesokhin AM, Paul B, Kaufman JL, Pianko M, Biran N, et al. Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nat Cancer. 2024;5:1459\u201364.","journal-title":"Nat Cancer"},{"key":"8203_CR33","doi-asserted-by":"crossref","unstructured":"Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F, et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6:eabd4344.","DOI":"10.1126\/sciimmunol.abd4344"},{"key":"8203_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood.2023022717","volume":"144","author":"J Kaminski","year":"2024","unstructured":"Kaminski J, Fleming RA, Alvarez-Calderon F, Winschel MB, Mcguckin C, Ho EE, et al. B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood. 2024;144:46\u201360.","journal-title":"Blood"},{"key":"8203_CR35","doi-asserted-by":"publisher","first-page":"e011690","DOI":"10.1136\/jitc-2025-011690","volume":"13","author":"J Kato","year":"2025","unstructured":"Kato J, Konishi T, Honda T, Maruta M, Nabe S, Masuda Y, et al. Bystander CAR(-)CD8(+) T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody. J Immunother Cancer. 2025;13:e011690.","journal-title":"J Immunother Cancer"},{"key":"8203_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12:44.","journal-title":"Exp Hematol Oncol"},{"key":"8203_CR37","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8:3562\u201375.","journal-title":"Blood Adv"},{"key":"8203_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature. 2024;627:646\u201355.","journal-title":"Nature"},{"key":"8203_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24:126.","journal-title":"Mol Cancer"},{"key":"8203_CR40","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-Cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322.","journal-title":"Clin Cancer Res"},{"key":"8203_CR41","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/biomedicines10051099","volume":"10","author":"BH Lee","year":"2022","unstructured":"Lee BH, Kim JH, Kang KW, Lee SR, Park Y, Sung HJ, et al. PVR (CD155) expression as a potential prognostic marker in multiple myeloma. Biomedicines. 2022;10:1099.","journal-title":"Biomedicines"},{"key":"8203_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.861","volume":"12","author":"ZY Liu","year":"2022","unstructured":"Liu ZY, Deng L, Jia Y, Liu H, Ding K, Wang W, et al. CD155\/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma. Clin Transl Med. 2022;12:e861.","journal-title":"Clin Transl Med"},{"key":"8203_CR43","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41375-024-02419-z","volume":"38","author":"L Martinez-Verbo","year":"2024","unstructured":"Martinez-Verbo L, Veselinova Y, Llinas-Arias P, Garcia-Prieto CA, Noguera-Castells A, Pato ML, et al. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. Leukemia. 2024;38:2722\u20136.","journal-title":"Leukemia"},{"key":"8203_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01490-0","volume":"17","author":"X Liu","year":"2025","unstructured":"Liu X, Sun Y, Lin B, Xiong H, Lu X, Tan B, et al. Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy. Genome Med. 2025;17:64.","journal-title":"Genome Med"},{"key":"8203_CR45","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41588-023-01554-0","volume":"55","author":"SR Mccutcheon","year":"2023","unstructured":"Mccutcheon SR, Swartz AM, Brown MC, Barrera A, Mcroberts Amador C, Siklenka K, et al. Transcriptional and epigenetic regulators of human CD8(+) T cell function identified through orthogonal CRISPR screens. Nat Genet. 2023;55:2211\u201323.","journal-title":"Nat Genet"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08203-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08203-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08203-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:05:45Z","timestamp":1766160345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08203-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8203"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08203-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of the First Affiliated Hospital of Nanjing Medical University Ethics Committee (No. 2023-SR-011). Informed consent was obtained from all participants prior to enrollment. All animal care and experimental procedures complied with the Guidelines for the Care and Use of Laboratory Animals of Nanjing Medical University, and were approved by Institutional Animal Care and Use Committee (IACUC) of Nanjing Medical University (No. 2201014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"890"}}